SIGNIFICANCE Of KI-67 EXPRESSION FOR PREDICTING The COURSE OF LOCALLY DIFFUSED HORMONE- DEPENDENT BREAST CANCER
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-2-2022-g.10608Keywords:
breast cancer, neoadjuvant hormone therapy, predicting the aggressiveness of the tumor process, Кі-67Abstract
Hormonal therapy is one of the main methods of comprehensive treatment for patients with locally advanced breast cancer (BC). Despite the intensity of studies devoted to the search for markers associated with the aggressiveness of the tumor process, today there is no unified point of view regarding the prognostic value of the proliferative activity of neoplasms in patients of this category. Aim: to investigate the features of Ki-67 expression in tumor cells of patients with hormone-dependent breast cancer who received neoadjuvant hormone therapy (NGT), and to find out the significance of this protein for predicting the aggressiveness of the tumor process. Object and methods: the study was conducted on the clinical material of 110 patients with stage II-III breast cancer who were receiving inpatient treatment at the Transcarpathian Antitumor Center during 2011–2020. All patients included in the study received NGT (tamoxifen or letrozole in mono-mode). The effectiveness of NGT was evaluated according to the data of mammography and ultrasound diagnosis of mammary glands according to RECIST 1.1 criteria. The study of Ki-67 expression in breast cancer cells was performed on paraffin sections of surgical material using the immunohistochemical method. Statistical processing of the obtained results was performed using the GraphPad Prism v.6.05 program, considering the nature of the distribution of the obtained data. Results: it was discovered that a positive effect was most often determined with the use of letrozole in the neoadjuvant regimen compared with the use of tamoxifen (75.0 vs. 60.0% of cases). High levels of Ki-67 expression in tumor cells were identified in patients with NGT-resistant neoplasms, which are characterized by stabilization and progression of the tumor process. It was shown that the 3-year recurrence-free survival of patients with hormone-dependent breast cancer treated with tamoxifen and letrozole in the neoadjuvant regimen was higher in the presence of a low level of expression of Ki-67 in tumor cells. Conclusion: it has been substantiated that the possibility of using Ki-67 expression indicators in tumor cells for predicting the aggressiveness of the course of hormone-dependent breast cancer and planning individualized treatment tactics.
References
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Intl J Cancer 2021; 149 (4): 778–89. doi: 10.1002/ijc.33588.
Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell 2020, 37 (4), 496–513. doi: 10.1016/j.ccell.2020.03.009.
Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, et al. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat 2019; 173 (3): 489–97. doi: 10.1007/s10549-018-5023-4.
Tang Y, Wang Y, Kiani MF, et al. Classification, treatment strategy, and associated drug resistance in breast cancer. Clin breast cancer 2016; 16 (5): 335–43. doi: 10.1016/j.clbc.2016.05.012.
Diaby V, Tawk R, Sanogo V, et al. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat 2015; 151 (1), 27–40. doi: 10.1007/s10549-015-3383-6.
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019; 321 (3): 288–300. doi: 10.1001/jama.2018.19323.
Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor–positive breast cancer: a systematic review and meta-analysis. JAMA Oncology 2016; 2 (11): 1477–86. doi: 10.1001/jamaoncol.2016.1897.
Barchiesi G, Mazzotta M, Krasniqi E, et al. Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci 2020; 21 (10): 3528. doi: 10.3390/ijms21103528.
Ali S, Rasool M, Chaoudhry H, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation 2016; 12 (3): 135. doi: 10.6026/97320630012135.
Manna S, Holz MK. Tamoxifen action in ER-negative breast cancer. Signal transduction insights 2016; 5: STI-S29901. doi: 10.4137/STI.S29901.
Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol 2018; 466: 2–14. doi: 10.1016/j.mce.2017.08.011.
Regan MM, Pagani O, Francis PA, et al. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 2015, 154(2), 275–86. doi: 10.1007/s10549-015-3612-z.
Iqbal BM, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. Med J Dr. DY Patil University 2016; 9(6): 674. doi: 10.4103/0975-2870.194180
Menon SS, Guruvayoorappan C, Sakthivel KM, et al. (2019). Ki-67 protein as a tumour proliferation marker. Clin Chimica Acta; 491: 39–45. doi: 10.1016/j.cca.2019.01.011.
Alco GUL, Bozdogan A, Selamoglu D, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol letters 2015; 9(3): 1046–54. doi: 10.3892/ol.2015.2852.
Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma 2018; 127(2): 175–86. doi: 10.1016/j.tibs.2018.08.004.
Sobecki M, Mrouj K, Colinge J, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res 2017; 77(10): 2722–34. doi: 10.1158/0008-5472.CAN-16-0707.
Mukherjee P, Sharma S, Sheikh ZA, et al. Correlation of clinico-pathologic and radiologic parameters of response to neoadjuvant chemotherapy in breast cancer. Indian J Cancer 2014; 51 (1): 25–9. doi: 10.4103/0019-509X.134610.
